InsidersTradesSigma
Follow the MASIMO CORP share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, MASIMO CORP has published 83 public disclosures. Market capitalisation: €9.4bn. The latest transaction was disclosed on 12 June 2026 (Disposition). Among the most active insiders: KIANI JOE E. The full history is openly available.
83
Insider Decl.
n/a
Thresholds
€3m
8 ops.
Buy Volume
€19m
12 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate MASIMO CORP Hold (neutral), based on 3 analysts. Average price target: US$180.00.
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,955 of 29,055 companies
44.7
score / 100
Value30
Quality60
FCF yld2.0%
Earn yld-1.6%
EV/EBITDA29.0x
ROE25%
Gross mgn62%
Net mgn-9.9%
Debt/EBITDA1.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 June 2026
Declarations83 total
9,309 sharesCommon StockSEC:0001104659-26-073526:0
2,101 shares0Common StockSEC:0000937556-26-000044:0
873 shares0Common StockSEC:0000937556-26-000042:0
15,000 shares0Common StockSEC:0000937556-26-000021:0
2,034 shares0Common StockSEC:0000937556-26-000019:0
11,141 shares@ US$132.96100.0% of flowCommon StockSEC:0000937556-26-000010:0
30,000 shares@ US$37.84100.0% of flowCommon StockSEC:0000937556-26-000008:0
2,474 shares@ US$152.43100.0% of flowCommon StockSEC:0000937556-25-000166:0
15,000 shares@ US$142.13100.0% of flowCommon StockSEC:0000937556-25-000142:0
126,888 shares0Common Stock, par value $0.001 per shareSEC:0001104659-25-085646:0
100 shares@ US$150.35100.0% of flowCommon StockSEC:0000937556-25-000125:0
Canonical exit: 10 Nov 2025 (T+90)
3,000 shares@ US$145.98100.0% of flowCommon StockSEC:0000937556-25-000123:0
Canonical exit: 9 Nov 2025 (T+90)
10,000 shares@ US$34.5122.9% of flowCommon StockSEC:0000937556-25-000084:0
1,790 shares0Common StockSEC:0000937556-25-000069:0
1,790 shares0Common StockSEC:0000937556-25-000075:0
1,383 shares0Common StockSEC:0000937556-25-000071:0
1,383 shares0Common StockSEC:0000937556-25-000073:0
1,790 shares0Common StockSEC:0000937556-25-000062:0
1,790 shares0Common StockSEC:0000937556-25-000066:0
1,790 shares0Common StockSEC:0000937556-25-000060:0
1,790 shares0Common Stock, par value $0.001 per shareSEC:0001104659-25-043642:0
2,053 shares@ US$166.131517.7% of flowCommon StockSEC:0000937556-25-000052:0
30,000 shares@ US$37.8477.1% of flowCommon StockSEC:0000937556-25-000045:0
15,000 shares0Common StockSEC:0000937556-25-000043:0
15,000 shares0Common StockSEC:0000937556-25-000039:0
25 of 83 declarations
关于 MASIMO CORP
Masimo Corp.（股票代码：MASI）是一家总部位于加利福尼亚州欧文市的美国医疗技术公司，在美国纳斯达克上市。Masimo由Joe Kiani于1989年作为一家私人车库初创公司创立，现已发展成为无创患者监测领域的全球领导者，在全球拥有超过7,000名员工。该公司的核心业务围绕生理监测技术，特别是脉搏血氧饱和度监测，但其产品组合已远远超出最初的突破，扩展到医院自动化、连接性和远程医疗的更广泛平台。（[masimo.com](https://www.masimo.com/company/masimo/about/?utm_source=openai)) Masimo的竞争地位建立在经过临床验证的创新和在高危护理环境中的强大渗透率之上。该公司强调其SET®技术是首个“通过运动和低灌注测量”的脉搏血氧饱和度监测技术，旨在在困难的临床条件下提供可靠的读数。这种性能定位一直是公司品牌和商业战略的关键差异化因素，有助于获得领先医院和将Masimo技术嵌入第三方监测设备的OEM合作伙伴的采用。（[masimo.com](https://www.masimo.com/company/about/?utm_source=openai)) 从产品角度来看，Masimo提供传感器、患者监护仪、连接模块、自动化解决方案以及rainbow®脉搏碳氧血氧饱和度监测、SedLine®脑功能监测、O3®区域血氧饱和度监测和呼气末二氧化碳监测等先进监测工具。Root®平台是公司生态系统的重要组成部分，因为它旨在将Masimo和第三方的多种监测功能结合到模块化架构中。这种更广泛的平台方法使Masimo能够服务于手术室、ICU、急诊护理以及选定的家庭护理或远程监测用例。（[masimo.com](https://www.masimo.com/products/sensors/brain-monitoring/sedline/?utm_source=openai)) 从地理上看，Masimo在欧文保留了强大的美国运营基地，同时在全球销售。该公司将自己定位为一家全球医疗技术提供商，其解决方案旨在改善结果、简化工作流程并将无创监测扩展到新的护理场所。其国际影响力通过直接商业化以及与主要医疗技术制造商的许可关系得到支持。（[masimo.com](https://www.masimo.com/company/masimo/about/?utm_source=openai)) 最近的发展对投资者尤其重要。2025年，Masimo公布了季度业绩，并继续推进新的临床证据和FDA批准的产品增强功能，包括O3®区域血氧饱和度监测的更新。2026年最重要的头条新闻是Masimo宣布同意被Danaher以每股180.00美元现金收购，总对价为9.9 billion美元，但须遵守惯例成交条件。对于关注SEC Form 4内幕交易活动的股票投资者而言，这种交易背景很重要，因为它将股票置于事件驱动的并购动态而非纯粹的独立运营业绩框架内。（[masimo.com](https://www.masimo.com/media/masimo-to-be-acquired-by-danaher?utm_source=openai))
